Treatment recommendations for radioimmunotherapy in follicular lymphoma

A consensus conference report

Thomas Elmer Witzig, Paul Fishkin, Leo I. Gordon, Stephanie A. Gregory, Samuel Jacobs, Roger MacKlis, Peter McLaughlin, Oliver Press, Andrew D. Zelenetz

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Radioimmunotherapy (RIT) with 90Y-ibritumomab tiuxetan or 131I-tositumomab combines a radiation-emitting radionuclide with an antibody targeting CD20 to treat B-cell non-Hodgkin lymphoma. Multiple studies demonstrate favorable RIT efficacy and safety profiles in follicular lymphoma (FL). The primary toxicity is reversible myelosuppression. Various FL treatment options include single-agent immunotherapy, radiation, chemoimmunotherapy, and RIT. Examining RIT clinical effects and position within treatment algorithms is important to optimal patient benefit. Clinical studies support using single-agent RIT in relapsed/refractory FL, in selected patients with new, untreated FL, and as consolidation after induction chemotherapy or chemoimmunotherapy. RIT as consolidation enhances response rates (with conversion of partial to complete responses following induction therapy) and prolongs disease control versus observation. The overall response rate is 60-80% in the relapsed setting. Time to progression is longer with low-bulk disease, fewer prior therapies, and retained rituximab sensitivity. RIT apparently does not preclude subsequent therapies or increase risk of secondary malignancies compared with chemotherapy's known risk. This article summarizes consensus recommendations for RIT and presents RIT treatment algorithms developed by hematologists/oncologists who regularly treat patients with FL. Maximizing RIT benefit requires healthcare providers to utilize algorithms assisting with treatment decisions.

Original languageEnglish (US)
Pages (from-to)1188-1199
Number of pages12
JournalLeukemia and Lymphoma
Volume52
Issue number7
DOIs
StatePublished - Jul 2011

Fingerprint

Radioimmunotherapy
Follicular Lymphoma
Therapeutics
Radiation
Induction Chemotherapy
B-Cell Lymphoma
Radioisotopes
Health Personnel
Non-Hodgkin's Lymphoma
Immunotherapy
Observation

Keywords

  • I-tositumomab
  • Y-ibritumomab tiuxetan
  • Follicular lymphoma
  • non-Hodgkin lymphoma
  • radioimmunotherapy
  • treatment algorithm

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Witzig, T. E., Fishkin, P., Gordon, L. I., Gregory, S. A., Jacobs, S., MacKlis, R., ... Zelenetz, A. D. (2011). Treatment recommendations for radioimmunotherapy in follicular lymphoma: A consensus conference report. Leukemia and Lymphoma, 52(7), 1188-1199. https://doi.org/10.3109/10428194.2011.570396

Treatment recommendations for radioimmunotherapy in follicular lymphoma : A consensus conference report. / Witzig, Thomas Elmer; Fishkin, Paul; Gordon, Leo I.; Gregory, Stephanie A.; Jacobs, Samuel; MacKlis, Roger; McLaughlin, Peter; Press, Oliver; Zelenetz, Andrew D.

In: Leukemia and Lymphoma, Vol. 52, No. 7, 07.2011, p. 1188-1199.

Research output: Contribution to journalArticle

Witzig, TE, Fishkin, P, Gordon, LI, Gregory, SA, Jacobs, S, MacKlis, R, McLaughlin, P, Press, O & Zelenetz, AD 2011, 'Treatment recommendations for radioimmunotherapy in follicular lymphoma: A consensus conference report', Leukemia and Lymphoma, vol. 52, no. 7, pp. 1188-1199. https://doi.org/10.3109/10428194.2011.570396
Witzig, Thomas Elmer ; Fishkin, Paul ; Gordon, Leo I. ; Gregory, Stephanie A. ; Jacobs, Samuel ; MacKlis, Roger ; McLaughlin, Peter ; Press, Oliver ; Zelenetz, Andrew D. / Treatment recommendations for radioimmunotherapy in follicular lymphoma : A consensus conference report. In: Leukemia and Lymphoma. 2011 ; Vol. 52, No. 7. pp. 1188-1199.
@article{327b4b8c45ee4c5cbcdc0c67a1b69bdc,
title = "Treatment recommendations for radioimmunotherapy in follicular lymphoma: A consensus conference report",
abstract = "Radioimmunotherapy (RIT) with 90Y-ibritumomab tiuxetan or 131I-tositumomab combines a radiation-emitting radionuclide with an antibody targeting CD20 to treat B-cell non-Hodgkin lymphoma. Multiple studies demonstrate favorable RIT efficacy and safety profiles in follicular lymphoma (FL). The primary toxicity is reversible myelosuppression. Various FL treatment options include single-agent immunotherapy, radiation, chemoimmunotherapy, and RIT. Examining RIT clinical effects and position within treatment algorithms is important to optimal patient benefit. Clinical studies support using single-agent RIT in relapsed/refractory FL, in selected patients with new, untreated FL, and as consolidation after induction chemotherapy or chemoimmunotherapy. RIT as consolidation enhances response rates (with conversion of partial to complete responses following induction therapy) and prolongs disease control versus observation. The overall response rate is 60-80{\%} in the relapsed setting. Time to progression is longer with low-bulk disease, fewer prior therapies, and retained rituximab sensitivity. RIT apparently does not preclude subsequent therapies or increase risk of secondary malignancies compared with chemotherapy's known risk. This article summarizes consensus recommendations for RIT and presents RIT treatment algorithms developed by hematologists/oncologists who regularly treat patients with FL. Maximizing RIT benefit requires healthcare providers to utilize algorithms assisting with treatment decisions.",
keywords = "I-tositumomab, Y-ibritumomab tiuxetan, Follicular lymphoma, non-Hodgkin lymphoma, radioimmunotherapy, treatment algorithm",
author = "Witzig, {Thomas Elmer} and Paul Fishkin and Gordon, {Leo I.} and Gregory, {Stephanie A.} and Samuel Jacobs and Roger MacKlis and Peter McLaughlin and Oliver Press and Zelenetz, {Andrew D.}",
year = "2011",
month = "7",
doi = "10.3109/10428194.2011.570396",
language = "English (US)",
volume = "52",
pages = "1188--1199",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Treatment recommendations for radioimmunotherapy in follicular lymphoma

T2 - A consensus conference report

AU - Witzig, Thomas Elmer

AU - Fishkin, Paul

AU - Gordon, Leo I.

AU - Gregory, Stephanie A.

AU - Jacobs, Samuel

AU - MacKlis, Roger

AU - McLaughlin, Peter

AU - Press, Oliver

AU - Zelenetz, Andrew D.

PY - 2011/7

Y1 - 2011/7

N2 - Radioimmunotherapy (RIT) with 90Y-ibritumomab tiuxetan or 131I-tositumomab combines a radiation-emitting radionuclide with an antibody targeting CD20 to treat B-cell non-Hodgkin lymphoma. Multiple studies demonstrate favorable RIT efficacy and safety profiles in follicular lymphoma (FL). The primary toxicity is reversible myelosuppression. Various FL treatment options include single-agent immunotherapy, radiation, chemoimmunotherapy, and RIT. Examining RIT clinical effects and position within treatment algorithms is important to optimal patient benefit. Clinical studies support using single-agent RIT in relapsed/refractory FL, in selected patients with new, untreated FL, and as consolidation after induction chemotherapy or chemoimmunotherapy. RIT as consolidation enhances response rates (with conversion of partial to complete responses following induction therapy) and prolongs disease control versus observation. The overall response rate is 60-80% in the relapsed setting. Time to progression is longer with low-bulk disease, fewer prior therapies, and retained rituximab sensitivity. RIT apparently does not preclude subsequent therapies or increase risk of secondary malignancies compared with chemotherapy's known risk. This article summarizes consensus recommendations for RIT and presents RIT treatment algorithms developed by hematologists/oncologists who regularly treat patients with FL. Maximizing RIT benefit requires healthcare providers to utilize algorithms assisting with treatment decisions.

AB - Radioimmunotherapy (RIT) with 90Y-ibritumomab tiuxetan or 131I-tositumomab combines a radiation-emitting radionuclide with an antibody targeting CD20 to treat B-cell non-Hodgkin lymphoma. Multiple studies demonstrate favorable RIT efficacy and safety profiles in follicular lymphoma (FL). The primary toxicity is reversible myelosuppression. Various FL treatment options include single-agent immunotherapy, radiation, chemoimmunotherapy, and RIT. Examining RIT clinical effects and position within treatment algorithms is important to optimal patient benefit. Clinical studies support using single-agent RIT in relapsed/refractory FL, in selected patients with new, untreated FL, and as consolidation after induction chemotherapy or chemoimmunotherapy. RIT as consolidation enhances response rates (with conversion of partial to complete responses following induction therapy) and prolongs disease control versus observation. The overall response rate is 60-80% in the relapsed setting. Time to progression is longer with low-bulk disease, fewer prior therapies, and retained rituximab sensitivity. RIT apparently does not preclude subsequent therapies or increase risk of secondary malignancies compared with chemotherapy's known risk. This article summarizes consensus recommendations for RIT and presents RIT treatment algorithms developed by hematologists/oncologists who regularly treat patients with FL. Maximizing RIT benefit requires healthcare providers to utilize algorithms assisting with treatment decisions.

KW - I-tositumomab

KW - Y-ibritumomab tiuxetan

KW - Follicular lymphoma

KW - non-Hodgkin lymphoma

KW - radioimmunotherapy

KW - treatment algorithm

UR - http://www.scopus.com/inward/record.url?scp=79959576404&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959576404&partnerID=8YFLogxK

U2 - 10.3109/10428194.2011.570396

DO - 10.3109/10428194.2011.570396

M3 - Article

VL - 52

SP - 1188

EP - 1199

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 7

ER -